IMAAVY® (nipocalimab-aahu) Demonstrates Durable, Over Two-Year Disease Control Across a Broad gMG Patient Population Johnson & Johnson has unveiled new clinical findings highlighting the long-term efficacy and safety of IMAAVY®…
Late-Breaking PRESERVE Trial Findings Assess XVIVO’s HOPE Preservation Strategy in Heart Transplantation XVIVO, a global medical technology company specializing in organ preservation and transplantation, has announced encouraging late-breaking preliminary results…
Kennel Connection Forms Exclusive Partnership with Petwealth to Deliver Clinical-Grade Pet Health Screening Across Pet Care Facilities Nationwide Kennel Connection, a leading provider of pet care facility management software and…
Kallyope Presents Phase 2b Data on Elismetrep, a Novel Migraine Therapy, at the American Academy of Neurology Annual Meeting Kallyope, a late-stage biopharmaceutical company focused on developing innovative treatments for…
As Federal Fast-Tracking of Psychedelic Treatments Gains Momentum, Segal Trials Is Poised to Advance the Next Stage of Clinical Development The recent federal directive encouraging the U.S. Food and Drug…
OrganaBio and RxMP Therapeutics Forge Manufacturing Alliance to Advance Development of RMP-402 Hemostatic Therapy OrganaBio and RxMP Therapeutics have announced a strategic manufacturing partnership aimed at advancing the development of…
Flatiron Health Highlights 18 Accepted Studies Leveraging Real-World Data for Presentation at ISPOR 2026 Flatiron Health has announced a significant presence at the ISPOR Annual Meeting 2026, taking place from…
Vistagen Secures FDA “Study May Proceed” Clearance for Refisolone IND, Advancing Phase 2 Development in Menopause-Related Vasomotor Symptoms Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company focused on advancing neuroscience…
Shields Health Solutions Collaborates with Columbus Regional Health to Expand Access to Specialty Pharmacy Care Shields Health Solutions, a leading specialty pharmacy integrator and accelerator in the United States, has…
Vyome Showcases Transformative Phase 2 Clinical Results for VT-1953 at AACR 2026 Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biotechnology company focused on developing innovative therapies for underserved conditions, has…
PureTech Reports Positive Phase 1b Topline Data for LYT-200 in Relapsed/Refractory High-Risk MDS and AML PureTech Health plc, a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value and…
Veristat to Acquire Certara’s Regulatory Affairs and Medical Writing Business Veristat, a science-first, full-service clinical research organization (CRO) and consultancy specializing in advancing complex therapies from early development through regulatory…